Abstract
Preemptive ganciclovir therapy has reduced the ocurrence of early cytomegalovirus (CMV) disease after hematopoietic stem cell transplantation (HSCT). However, late disease is increasingly reported. We describe two patients who developed late CMV central nervous system (CNS) disease after haploidentical HSCT. Direct genotypic analysis was employed to examine the presence of ganciclovir resistance. One patient had a mixed viral population in the CSF, with coexistent wild type and mutant UL97 sequences. The presence of 2 different strains was confirmed by subclone sequencing of the UL54 gene. One of the strains was different from the concurrent blood strain.
The second patient had resistant variant in the lungs . These cases raise concern about the changing natural history of CMV disease in HSCT, with emergence of previously uncommon manifestations following prolonged prophylaxis. Under these circumstances the CNS may be a sanctuary site, where viral persistence and antiviral drug resistance could result from limited drug penetration.
Introduction
Despite the availability of potent antiviral drugs, cytomegalovirus (CMV) remains a significant complication after hematopoietic stem cell transplantation (HSCT) (1) . The widespread use of prophylactic and preemptive ganciclovir therapy has reduced the occurrence of early CMV disease, however the development of late disease is increasingly recognized (2, 3) .
Prolonged ganciclovir exposure may also lead to the selection of ganciclovir-resistant strains (4, 5) . Ganciclovir resistance results mainly from impaired phosphorylation of the drug, caused by mutations in the CMV UL97 phosphotransferase (5) (6) (7) (8) . Less frequently, resistance is caused by mutations in the UL54 (DNA polymerase) gene (9, 10) .
Until recently, ganciclovir resistance has been described mainly among AIDS patients receiving prolonged maintenance therapy (4, 7, 11) . Over the last few years, ganciclovir resistance has been increasingly reported among solid-organ transplant recipients, especially those with high viral load and lengthened antiviral exposure (12, 13) . Thus far, there have been only anecdotal reports of ganciclovir resistance among HSCT recipients (14) .
Recently, we and others have described the emergence of ganciclovir resistance in children after HSCT (15, 16) . Studies in adult HSCT recipients, however, demonstrated the absence of resistance after up to 56 days of cumulative ganciclovir exposure (17). Yet, with improved survival after HSCT, change in immunosuppressive regimens, and longer duration of ganciclovir exposure, drug resistance in association with late disease is expected to become a growing problem in this setting. Here, we report two cases of lateonset CMV central nervous system (CNS) disease, which developed during preemptive antiviral therapy after HSCT. Direct genotypic analysis was employed to examine the role of drug resistance and compartmental differences among infecting strains in the development of this unusual manifestation.
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Patients and Methods

Patients:
The two patients were treated at the Rambam Medical Center, where a total Amplification and sequencing of the CMV UL97 and UL54 genes:
Direct PCR sequencing was performed as described (7,10,15) using overlapping primer pairs encompassing nucleotides 1207 to 1979 (UL97), and 900 to 3000 (UL54). These regions include all of the known resistance mutations.
For subclone sequencing, PCR products were inserted into p-Gem-T vector, transformed into E. coli DH-5 , and both strands of the inserts were sequenced. As demonstrated in AIDS patients, the presence of multiple strains may be associated with more severe disease (25). Compartmental differences among infecting strains, found in the 2 patients, suggest that direct genotypic analysis in the blood may not always predict the resistance profile in the tissues.
Results and Discussion
CMV
In conclusion, the cases described herein raise concern about the changing natural history of HCMV disease in HSCT. Under these 
